American Pharmaceutical Partners Inc (Schaumburg, Ill) recently announced FDA approval to launch Piperacillin for Injection USP, the generic equivalent of Wyeth?s Pipracil. Piperacillin is a third-generation antibiotic indicated for the treatment of serious infections caused by designated susceptible microorganisms such as Pseudomonas aeruginosa. This antibiotic is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. These microorganisms are found in a variety of conditions, including intra-abdominal infections, urinary tract infections, gynecologic infections, septicemia, lower respiratory tract infections, skin and skin-structure infections, bone and joint infections, and uncomplicated gonoccocal urethritis. For more information, visit www.appdrugs.com.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs